Related posts

13 Recession-Proof Stocks for Portfolio SafetyStocks climb to start weekWinning and losing stocks and sectors
Investor Insights

This summary was created by AI, based on 26 opinions in the last 12 months.

Johnson & Johnson (JNJ) faces challenges stemming from ongoing talcum powder litigation and a recent acquisition that impacted its credit rating. Despite these issues, many experts view JNJ as a defensive stock with stable earnings and cash flow, supported by a consistent dividend yield of around 3-3.5%. Analysts highlight that the company's diversified operations across consumer health, pharmaceuticals, and medical devices position it well for future growth. Recent social media mentions have surged, reflecting renewed interest in the stock. The consensus among experts suggests that JNJ is a long-term hold, with potential upside once the legal overhang is resolved and a focus shifts back to its solid fundamentals.

Consensus
Hold
Valuation
Undervalued
Similar
Pfeizer, PFE
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 17/24, Up 7%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with JNJ is progressing well.  To remain disciplined, we recommend trailing up the stop (from $133) to $146 at this time.  

WEAK BUY

It reports Wednesday. They're still dealing with the talcum power lawsuit and a new acquisition for $14 billion which hurt JNJ's pristine credit rating. The market has turned against this sector, but he feels you reinvest their juicy dividend.

DON'T BUY

Is a hodge-podge of consumer products, some medical business and an also-ran in businesses like hips and knees. This has always traded at a premium for being a well-run consumer package company that money managers can't get fired for owning. It's so big that it needs to be broken up.

PAST TOP PICK
(A Top Pick May 09/24, Up 0.2%)

You can own, collect the dividend and in coming years will likely be higher. This is mixed in with current worries over healthcare stocks, but this will pass. JNJ has stable earnings and cash flow. Happy to hold on.

premium

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Premium members

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. Social media mentions are up 250% in the past 24h.

RISKY

JNJ hasn't been this cheap in many years, pays a 3.5% yield and boasts a super balance sheet. The sector is unloved, though. If you can handle the pain, you can get some gain.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The consumer product monster has increased debt lately, but analysts feel comfortable with the low debt to earnings ratio.  This is allowing the company to continue growing cash reserves.  It trades at 24x earnings and supports a 20% ROE.  We recommend setting a stop-loss at $133 looking to achieve $174 -- upside potential of 19%.  Yield 3.3%

(Analysts’ price target is $174.28)
BUY ON WEAKNESS

Pays a 3.3% yield and has great drugs. Even with the talcum powder litigation, he'd buy it here.

Unspecified

It doesn't grow quickly, has a modest dividend and is diversified.

HOLD

Concerns in pharmaceutical segment, as one particular drug facing patent cliff next year. Talc litigation still an overhang; once done, can focus on turning around core operations. Diversified, likes the pipeline. You can afford to be patient.

BUY

It is in the medical devices and pharma spaces and has spun off the consumer care division. The overhang is the talcum powder litigation. He hopes it will be settled before too long and then investors can concentrate on the growth aspect of the stock. It has set aside 8 to 10 billion dollars for a settlement.

HOLD
Sell now?

Stock performance somewhat disappointing. She'd keep holding. After KVUE spinoff now simply a medical device, medical tech, and pharma company. Some drugs are going off patent, but successful in developing pipeline. Company still expects revenue to grow slightly as time goes on.

Very strong balance sheet, AAA credit rating. Nice dividend, increases every year. Ongoing talc litigation is the overhang, but positive steps toward resolution. Then PE multiple should lift. 

WATCH

They report Tuesday. Their legal troubles could be ending, which would shift focus to their earnings. He think he will like what he sees.

PAST TOP PICK
(A Top Pick Oct 05/23, Up 5%)

He owns it partly for the defensive nature and partly for the business which leads to a focus on pharmaceuticals.

PAST TOP PICK
(A Top Pick Sep 11/23, Up 5%)

They spun off personal products, so JNJ is more a medical device company. They have huge cash from that spin-off, which could allow buying a medical device or biotech company. The talcum powder lawsuit is settling, too. They've raised their dividend for 54 years. 

Showing 1 to 15 of 609 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 4

Total Signals / Votes : 20

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 20 stock analysts published opinions about JNJ-N. 13 analysts recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

20 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2025-03-18, Johnson & Johnson (JNJ-N) stock closed at a price of $163.77.